Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

hVIVO lands two new contracts worth £9mln

The specialist in human disease models said it is in talks with pharmaceutical companies over further deals
petrie dish
An order has come in for a further two respiratory syncytial virus human challenge studies

hVIVO PLC (AIM:HVO), a specialist in human disease models, said it is in talks with pharmaceutical companies over further deals after landing new contracts worth £9mln.

Updating the market, it said it will provide an unnamed “leading global biopharmaceutical company” with two respiratory syncytial virus (RSV) human challenge studies. This follows last month’s £11.9mln RSV agreement.

Contagious, respiratory syncytial virus causes the common cold, for which there is no effective cure.

Revenue impact next year

The revenue impact of the latest deal will be felt mainly next year.

“The recent significant new contract wins reinforce our leading position in human disease models based upon viral and allergen challenge and are a testament to our industry leading RSV-human challenge model,” said chairman, Dr Trevor Phillips.

“We have the strongest sales pipeline we have had for several years.

“We remain actively engaged in several discussions with other pharmaceutical companies for contracting studies across our current challenge portfolio, including allergen, asthma, human rhinovirus, influenza and RSV.”

High levels of demand

Phillips said hVIVO continued to experience “high levels of interest” from global pharma companies interested in new challenge models for RSV, asthma and chronic obstructive pulmonary disease.

“With the significant demand for our services across the entire portfolio, we expect to convert a growing number of these opportunities into contracts that will further validate our service offerings and enhance our revenue in 2019 and beyond," he added.

In a separate announcement, hVIVO said former chairman Jaime Ellertson is leaving the board with immediate effect.

The shares rose 10% at 64.60p, valuing the business at just shy of £51mln.

--- Adds share price ---


View full HVO profile View Profile

hVIVO PLC Timeline

September 02 2016

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use